e-Drug3D

2102

FRUQUINTINIB

INN
FRUQUINTINIB

cas 1194506-26-7

CLASS

ANTINEOPLASTIC
TREATMENT OF METASTATIC COLORECTAL CANCER (MCRC)
INHIBITOR OF VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTORS (VEGFR)-1, -2, AND -3

ROUTE (list)

ORAL

ATC code

L01EK04

PK parameters

Tmax 2 HOUR
VD 46 LITER
Cl 0.8 LITER / HOUR
PPB 95 PERCENT
t1/2 42 HOUR

Solubility

0.9 MICROGRAM PER MILLILITER AT PH 6.8

Target

TARGET VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTORS (VEGFR)-1, -2, AND -3

Download SDF file

3-Benzofurancarboxamide, 6-[(6,7-dimethoxy-4-quinazolinyl)oxy]-N,2-dimethyl- (ACI)

Formula:
C21H19N3O5

Calculated chemical properties:

MW 393.39
NB_atoms 29
XLogP 3.85
PSA 92.332
NB_HD 1
NB_HA 8
fsp3 0.19
Lipinski(0=no;1=yes) 1

FDA
NDA 217564 (pdf not found) INN (FRUQUINTINIB) FRUZAQLA (TAKEDA PHARMS USA) APPROVAL= AP YEAR= 2023 NEWMOLECULARENTITY